TY - JOUR
T1 - Subsequent risks for cervical precancer and cancer in women with low-grade squamous intraepithelial lesions unconfirmed by colposcopy-directed biopsy
T2 - Results from a multicenter, prospective, cohort study
AU - Matsumoto, Koji
AU - Hirai, Yasuo
AU - Furuta, Reiko
AU - Takatsuka, Naoyoshi
AU - Oki, Akinori
AU - Yasugi, Toshiharu
AU - Maeda, Hiroo
AU - Mitsuhashi, Akira
AU - Fujii, Takuma
AU - Kawana, Kei
AU - Iwasaka, Tsuyoshi
AU - Yaegashi, Nobuo
AU - Watanabe, Yoh
AU - Nagai, Yutaka
AU - Kitagawa, Tomoyuki
AU - Yoshikawa, Hiroyuki
N1 - Funding Information:
The authors thank Dr. Tadahito Kanda (Center for Pathogen Genomics, National Institute of Infectious Diseases, Tokyo, Japan) for his comments on the study design and the manuscript; Mr. Masafumi Tsuzuku (Department of Cytopathology, Cancer Institute Hospital, Japanese Foundation of Cancer Research, Japan) for his cytologic review; many other researchers who facilitated this study; and all the women who participated in the study. This work was supported by a grant from the Ministry of Education, Science, Sports and Culture of Japan (grant # 12218102).
PY - 2012/6
Y1 - 2012/6
N2 - Objective To investigate the natural course of low-grade squamous intraepithelial lesions (LSILs) that cannot be histologically confirmed by colposcopy-directed biopsy. Methods In a multicenter, prospective, cohort study of Japanese women with LSILs, we analyzed the follow-up data from 64 women who had a negative biopsy result at the initial colposcopy (biopsy-negative LSIL) in comparison with those from 479 women who had a histologic diagnosis of cervical intraepithelial neoplasia grade 1 (LSIL/CIN1). Patients were monitored by cytology and colposcopy every 4 months for a mean follow-up period of 39.0 months, with cytologic regression defined as two consecutive negative smears and normal colposcopy. Results In women with biopsy-negative LSILs, there were no cases of CIN3 or worse (CIN3+) diagnosed within 2 years; the difference in the 2-year risk of CIN3+ between the two groups was marginally significant (0 vs. 5.5%; P = 0.07). The cumulative probability of cytologic regression within 12 months was much higher in the biopsynegative LSIL group (71.2 vs. 48.6%; P = 0.0001). The percentage of women positive for high-risk human papillomaviruses (hrHPVs) was significantly lower in the biopsynegative LSIL group than in the LSIL/CIN1 group (62.1 vs. 78.4%; P = 0.01); however, the 12-month regression rate of biopsy-negative LSIL was similar between hrHPV-positive and -negative women (67.3 vs. 74.4%, P = 0.73). Conclusion In women with biopsy-negative LSILs, the risk of CIN3+ diagnosed within 2 years was low; furthermore, approximately 70% underwent cytologic regression within 12 months, regardless of HPV testing results. Biopsy-negativeLSILsmay represent regressing lesions rather than lesions missed by colposcopy.
AB - Objective To investigate the natural course of low-grade squamous intraepithelial lesions (LSILs) that cannot be histologically confirmed by colposcopy-directed biopsy. Methods In a multicenter, prospective, cohort study of Japanese women with LSILs, we analyzed the follow-up data from 64 women who had a negative biopsy result at the initial colposcopy (biopsy-negative LSIL) in comparison with those from 479 women who had a histologic diagnosis of cervical intraepithelial neoplasia grade 1 (LSIL/CIN1). Patients were monitored by cytology and colposcopy every 4 months for a mean follow-up period of 39.0 months, with cytologic regression defined as two consecutive negative smears and normal colposcopy. Results In women with biopsy-negative LSILs, there were no cases of CIN3 or worse (CIN3+) diagnosed within 2 years; the difference in the 2-year risk of CIN3+ between the two groups was marginally significant (0 vs. 5.5%; P = 0.07). The cumulative probability of cytologic regression within 12 months was much higher in the biopsynegative LSIL group (71.2 vs. 48.6%; P = 0.0001). The percentage of women positive for high-risk human papillomaviruses (hrHPVs) was significantly lower in the biopsynegative LSIL group than in the LSIL/CIN1 group (62.1 vs. 78.4%; P = 0.01); however, the 12-month regression rate of biopsy-negative LSIL was similar between hrHPV-positive and -negative women (67.3 vs. 74.4%, P = 0.73). Conclusion In women with biopsy-negative LSILs, the risk of CIN3+ diagnosed within 2 years was low; furthermore, approximately 70% underwent cytologic regression within 12 months, regardless of HPV testing results. Biopsy-negativeLSILsmay represent regressing lesions rather than lesions missed by colposcopy.
UR - http://www.scopus.com/inward/record.url?scp=84862862221&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862862221&partnerID=8YFLogxK
U2 - 10.1007/s10147-011-0280-9
DO - 10.1007/s10147-011-0280-9
M3 - Article
C2 - 21748261
AN - SCOPUS:84862862221
SN - 1341-9625
VL - 17
SP - 233
EP - 239
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
IS - 3
ER -